Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc AZN to jointly develop ...

Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca (AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell ...

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

Managing stress is crucial when you have EGFR-positive lung cancer, as chronic stress can negatively impact your body’s immune system and contribute to cancer growth and treatment resistance. Stress ...

NSCLC is the most frequent histological subtype of lung cancer, accounting for approximately 85% of patients with lung cancer. NSCLC includes a variety of different lung cancers, most notably ...

Elizabeth Dennis describes the testing process following a new lung cancer diagnosis. Initial tissue biopsy is sent for next-generation sequencing (NGS), although repeat tissue sampling or liquid ...

Racura Oncology Limited (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed ...

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly ...

Treatment varies based on the patient's functional status, comorbidities and tumor stage, as well as the molecular characteristics of the disease. While patients who have stage I, II or III non-small ...

Learn why comprehensive biomarker testing is essential before starting any lung cancer treatment. Hear from patients and ...